Compare CVS Health Corp (CVS) vs Honest Company Inc (HNST) Price & Performance

CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.

The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.

HNST trades at $3.90, down 2.74% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting expectations, while revenue trends show volatility with 2025 revenue at $371.32M. Gross margins improved to 33.89%, but net income remains negative at -$15.69M for 2025. Positive cash flow from operations of $15.12M supports liquidity, though profitability challenges persist.

Outlook is mixed: analyst consensus leans hold (50%) with 30% buy ratings, citing improved fundamentals but limited upside. Key risks include sustained negative net margins and competitive pressures in personal care. The stock's high P/E of 48.83 suggests premium valuation despite lack of profits, requiring careful risk assessment for investment.